Jazz Pharmaceuticals (JAZZ) NewsBite - JAZZ Rises on Clinical Trial Data
Posted: Thursday, June 25, 2009 12:28 PM EDT
By: Market Intelligence Center Staff
Jazz Pharmaceuticals (NGM: JAZZ) opened at $4.57. So far today, the stock has hit a low of $4.50 and a high of $5.27. JAZZ is now trading at $4.89, up $1.64 (50.46%). Over the last 52 weeks the stock has ranged from a low of $.51 to a high of $8.95. Shares of JAZZ are trading higher on news that the second of two Phase III clinical trials of sodium oxybate for the treatment of fibromyalgia met its primary endpoints. This could be a good sign for JAZZ. Technical indicators for the stock are bullish and S&P does not currently have a STARS rating for JAZZ. We will just watch this one for now. There are no hedged trades we like the look of for JAZZ. [ABR-Seven Summits Strategic Investments NewsBite]
CLICK HERE: FREE Jazz Pharmaceuticals (JAZZ) Stock ReportSee what our analysts have uncovered about Jazz Pharmaceuticals (JAZZ).